hotspot -WSS

hotspot

author：knowledge 2025-09-29 01:06:46 - browse：4

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Empower primary care with adequate payments and technology

leisure time

WSS

AltruBio raises $225 million to develop ulcerative colitis drug

CDC's new outbreak response network to include Northeastern

Senate HELP committee spars over health care workforce policies

Warren pushes Witty on UnitedHealth's control over physicians

Deliver public health messages at the right time

Novel spinal cord stimulator treats paralysis without surgery

hotspot

hotspot

focus

Apple is now the first public company to be valued at $3 trillion

HHS's proposed rule does nothing to address the climate crisis

Hollywood unions extend contract negotiations for actors

Has Bernie Sanders reached the limit of his pharma bullying effort?

Virginia high school admissions case could be legal follow

Lasker Awards 2023: Winners in biomedical research

Novavax promises a turnaround & Lilly roils the obesity market

GSK’s asthma push continues as drug succeeds in Phase 3 trials

New air purifier tech could be key to improving indoor air quality

What Congress can do to address the rural doctor shortage

explore

EpiPen alternative approval delay highlights citizen petition issue

STAT Virtual Event: Putting AI to the Test

Microbiome research is starting to find links to chronic diseases

Second xenotransplant done with gene

Second xenotransplant done with gene

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

explore

leisure time

focus

Wikipedia